U.S., Feb. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07416942) titled 'Omics of Rituximab-resistance' on Feb. 10.
Brief Summary: The CONFUCIUS project aims to establish a personalised medicine framework for MN patients by integrating pharmacogenomics with other -omics technologies in order to identify biomarkers that predict response to RTX, ultimately enabling optimized treatment selection. Using a multiomics approach, we will analyse genetic variants, serum and kidney proteomics, and serum metabolomics profiles from a well-characterised retrospective cohort of MN patients to uncover predictive biomarkers of RTX response.
This is a non-pharmacological interventional study, conducted on biological sam...